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As the number of cases of COVID-19 (SARS-
CoV-2) rise in the United States (US), the num-
ber of severe cases (those requiring intensive
care unit [ICU] admission) rise with it. Initially,
the estimate for severe cases was approximated
at 5% based on experience from China.1,2 How-
ever, the World Health Organization (WHO)’s
estimate from China for severe and critical cases
is near 20% (Table 1).3 The primary clinical fea-
ture of COVID-19 is pneumonia, the severity of
which directs the clinical course; it has been
estimated that, of patients admitted to the ICU,
up to half may require either invasive or nonin-
vasive ventilatory support.4 This has created an
unprecedented situation for emergency and criti-
cal care medicine.
Clinical Manifestations
Fever, cough, and dyspnea are the most com-
mon signs of COVID-195; it is a respiratory tract
infection with pneumonia being the hallmark of
more severe illness and the acute respiratory dis-
tress syndrome (ARDS), a serious complication
and manifestation of its most critical form
(Table 1).5 While there are no symptoms that dis-
tinguish COVID-19 from other causes of acute
hypoxemic respiratory failure,6,7 there appear to
be distinct features (e.g., anosmia) and/or findings
on chest computed tomography (e.g., patchy
ground glass opacities in the lung periphery)8 that
could provide important clues, particularly if the
result of a diagnostic test is unavailable. Critical
illness often includes multi-organ dysfunction or
failure and severe COVID-19 appears to be no dif-
ferent. Early reports from China cite an incidence
of acute kidney injury in ~ 30% of patients,
cardiac complications in ~ 23%, and liver dys-
function in ~ 29%.5 In addition, nausea and/or
vomiting has been reported in 5% of cases and in
some instances may be intractable. Complications
such as cardiac arrhythmias, myocardial ischemia
(with elevations in troponin), and cardiac arrest
have also been reported.9 Patients with underly-
ing cardiovascular disease (CVD) may be at
increased risk of these complications. Patients
who require mechanical ventilation represent the
most critically ill, and mortality has been reported
as high as 62%.5 A cytokine storm syndrome
resembling a secondary hemophagocytic lympho-
histiocytosis-like presentation has been identified
in up to 50% of patients and may predict wors-
ened outcomes.10 Healthcare utilization is a major
concern, as these patients often require prolonged
mechanical ventilation prior to either recovery or
death, leading to equipment and potential medi-
cation shortages during times of surge.
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SpO2 = peripheral capillary oxygen saturation.
a
Acute respiratory distress syndrome per the Berlin definition.38
b
Severe cardiac complications include ischemia, cardiac arrest,
acute heart failure, and arrhythmias.
Respiratory and Cardiovascular Complications
One of the most serious complications of
COVID-19 is ARDS, representing a major risk
factor for death.5 The management of these
patients should follow evidence-based treatment
guidelines.11,12 This includes the use of lung-
protective ventilation, conservative fluid strate-
gies, neuromuscular blocking agents to facilitate
ventilator synchrony, prone positioning as
appropriate, and empirical antibiotics for sus-
pected bacterial co-infection with aggressive de-
escalation. In the setting of refractory hypox-
emia, extracorporeal membrane oxygenation
should be considered.
Serious cardiovascular complications can also
occur and patients with underlying CVD may be
at greatest risk. This may be related to the fact that
COVID-19 enters cells via the angiotensin-con-
verting enzyme (ACE)2 receptor. The concern is
that in experimental studies, administration of
either ACE inhibitors or angiotensin receptor
blockers (ARBS) resulted in the upregulation of
ACE2 expression in the heart.13 Although these
findings have not been replicated in human stud-
ies or in the setting of COVID-19, such potential
upregulation of ACE2 by ACE inhibitors or ARBs
has resulted in speculation that these medications
might worsen infection or predispose patients to
myocardial injury. There are also preclinical data
that show that ARB-induced upregulation of the
ACE2 receptor lessens ARDS severity. In a pre-
clinical model of severe acute respiratory syn-
drome (SARS Co-V), treatment with losartan
improved angiotensin signaling, ARDS, and sur-
vival,14 and severe COVID infections are associ-
ated with low (not high) expression of ACE2.15 In
aggregate, the pre-clinical data are conflicting but
it may be that a dysregulated angiotensin system,
rather than a specific medication, drives differ-
ences in outcomes. In the absence of definitive
evidence, concern about the use of ACE inhibitors
and ARBs was recently addressed in a joint state-
ment from the Heart Failure Society of America,
the American College of Cardiology, and the
American Heart Association.16 They collectively
recommend that these therapies neither be with-
held nor added in COVID-19 patients based on
lack of human data and preclinical data suggesting
benefit from their use. In the emergency depart-
ment and ICU, treatment of CV complications
should be managed by established therapies and,
when applicable, advanced cardiac life support
protocols (https://www.acls.net/aclsalg.htm)
should be used. However, it may be prudent to
avoid the use of angiotensin II for the treatment of
refractory shock until more information regarding
the interaction between COVID-19 and the renin-
angiotensin-aldosterone system is available.
Mitigation and Treatment
Personal protective equipment (PPE) is fore-
front in mitigating nosocomial infection and pro-
tecting healthcare workers. Larger hospitals are
also establishing dedicated respiratory infectious
containment units specifically for the treatment of
COVID-19 patients regardless of whether they
require mechanical ventilation. Staffing models
for these units may preferentially include provi-
ders already recovered from the virus as the pan-
demic evolves, given a theoretical potential for
relative immunity, though this does not mitigate
the recommendations for stringent PPE practices.
Pharmacists can play an important role in
improving the safety of fellow healthcare practi-
tioners entering and exiting rooms of those with
COVID-19 and reduce PPE use through medica-
tion regimen optimization. As appropriate, medi-
cation administration times can be standardized
to limit the number of different medication
administrations throughout the day (i.e., retiming
medications from 0600, 0700, and 0800 to all be
administered at 0700). The use of long-acting
medication formulations, when available, may
also limit the number of daily required medica-
tion administrations. Additionally, subcutaneous
insulin may be preferred to intravenous insulin
infusions as a way to reduce frequent entry into
patient rooms. Creative efforts to further reduce
exposure and the need for multiple PPEs should
be explored and may include positioning equip-
ment outside of the patient room (e.g., intra-
venous medication infusion pumps).
Pharmacotherapy for COVID-19 is limited and
treatment remains primarily supportive. At the
time of writing, no COVID-19–specific pharma-
cotherapies were approved by the FDA (on
March 29, the FDA authorized emergency use of
chloroquine and hydroxychloroquine). Never-
theless, the gravity of the situation has led to a
flurry of anecdotal pharmacotherapy approaches
in the ICU. Without solid evidence, nearly half
of the patients in a recent report were treated
with antiviral agents.5
Antiviral Agents
There is presently no conclusive evidence that
currently available antiviral agents have efficacy
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against COVID-19. Furthermore, safety of these
agents has not been established in COVID-19
patients. In fact, a recently published study of
lopinavir-ritonavir compared with standard care
showed that combination therapy had no thera-
peutic advantage over supplemental oxygen,
noninvasive or invasive ventilation, antibiotics,
vasopressors, renal-replacement therapy, and
extracorporeal membrane oxygenation that con-
stituted the standard care arm of the study.17
The study randomized 199 patients 1:1 in an
unblinded manner. The absence of efficacy was
met with a nearly two-fold higher incidence of
grade 3–4 adverse events (AEs) including lym-
phopenia, which occurred in 12.6% of treated
patients compared with 5% of patients who
received standard care. In addition to the
absence of evidence of efficacy, when contem-
plating unproven, anecdotal therapies, we urge
clinicians to consider the risk of AEs that could
further compromise critically ill patients.
In the US, remdesivir (which is not commer-
cially available) was given to the country’s first
patients with SARS-CoV-2 pneumonia under
compassionate use.18 The activity of remdesivir
against COVID-19 has been demonstrated in
preclinical animal models,19 but its efficacy and
safety in humans are still under investigation.
There are several ongoing trials of remdesivir in
both the US and China. These studies will
include both mild to moderately ill
(NCT04252664) and severely ill COVID-19
patients (NCT04257656) as well as an adaptive
treatment trial (NCT04280705).5
Glucocorticoids
The use of intravenous glucocorticoids is con-
troversial in the treatment of severe COVID-19
pneumonia and ARDS. The WHO does not rec-
ommend their routine use in COVID-19
patients.3 This stems for experience during the
SARS Co-V epidemic9,20 for which they were
commonly used, and findings suggest in viral
infection, they may be harmful (i.e., delayed
viral clearance).21 However, in the treatment of
ARDS there is evidence that steroids reduce the
duration of mechanical ventilation,22,23 and a
recent multi-center study of dexamethasone
demonstrated a mortality benefit.23 A detailed
discussion of the use of steroids in COVID-19
patients is beyond the scope of this report. How-
ever, in the context of therapeutic decision mak-
ing, consideration should be given to the
efficacy data for steroid use in ARDS, most of
which was generated from rigorously conducted
clinical trials.
Immunomodulating Agents
Tocilizumab, an interleukin (IL)-6 receptor
antagonist (monoclonal antibody), is FDA
approved for the treatment of rheumatoid arthri-
tis and is currently part of several studies listed
on ClinicalTrials.gov. Its manufacturer, Roche,
has received approval from China and the US to
conduct a phase III randomized, placebo-con-
trolled, double-blind trial. The cytokine, IL-6, is
an inflammatory cytokine that is central to the
immune response to infection.24 In a recent
description of the clinical course of hospitalized
COVID-19, serum concentrations of IL-6 were
elevated in nonsurvivors compared with sur-
vivors (11.0 vs 6.3 pg/ml; p<0.0001).25 Inter-
leukin-6 has also been shown to be elevated in
patients with ARDS and is considered a candi-
date biomarker of mortality in these patients.26
Sarilumab, a subcutaneously administered IL-6
inhibitor also FDA approved for the treatment of
rheumatoid arthritis, is also being examined in
several studies for intravenous administration for
treatment of COVID-19. However, in the
absence of safety and efficacy data from random-
ized control trials, we do not recommend the
routine use of these agents.
Interferon-alpha (a) has been proposed as a
candidate therapeutic for COVID-19 in the
National Health Commission of the People’s
Republic of China for treatment of COVID-19
(version 6).27 Interferon-a plays a pivotal role in
host defense of viral infection and is FDA-ap-
proved for the treatment of hepatitis B and a
number of different types of cancer. A small
open-labeled study of patients with SARS Co-V
showed that in combination with glucocorti-
coids, subcutaneously administered interferon-a
reduced the time to improved oxygen saturation
and resulted in a more rapid resolution of chest
radiographic findings.28 The recommendation
here, however, is for the use of inhaled adminis-
tration of the drug. The rationale for its use may
be to target the site of action and to avoid sys-
temic AEs (which can be severe, granulocytope-
nia has been reported in up to 90% of patients).
Presently, to the best of our knowledge, there are
no prospective studies of inhaled interferon-a
that demonstrate its safety and efficacy and we
are not aware of any planned or ongoing
COVID-19 studies in the US that will test its
safety and efficacy. However, there are a few
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studies that are utilizing it in combination with
standard care or anti-viral agents. Given the
potential for serious AEs, we do not advise anec-
dotal use in critically ill patients with COVID-19.
Other Therapeutics
The use of hydroxychloroquine for the treat-
ment of COVID-19 has received a lot of press
recently. Chloroquine and hydroxychloroquine
are anti-inflammatory drugs that are primarily
used to treat uncomplicated malaria and rheu-
matic diseases but detailed studies of the specific
mechanism(s) of action of these drugs have not
been conducted29; hydroxychloroquine is pre-
ferred because of it has a more favorable AE
profile than chloroquine. The rationale for the
use of hydroxychloroquine seems to be because
of its presumed anti-viral action against COVID-
19 by changing the glycosylation of the ACE2
receptor, presumably interfering with viral bind-
ing and invasion, but evidence for this is from
in vitro and small observational studies.30–32
The addition of azithromycin to hydroxychloro-
quine has been explored, not only for possible
bacterial co-infection (although less likely based
on current evidence), but for its potential anti-
viral action, for which there is also limited evi-
dence.33 Notably, in the most recent trial of azi-
thromycin combined with hydroxychloroquine
in hospitalized patients, which was neither ran-
domized nor blinded, only 20 of the enrolled 26
patients that received hydroxychloroquine (six
of whom also received azithromycin) were
included in the analysis.32 The authors reported
a hydroxychloroquine-induced reduction in the
percentage of patients with positive tests but of
the six patients that were not included in the
analysis, three were transferred to the ICU and
one patient died. Therefore, given the results of
this study and known risk of azithromycin alone
or in combination with hydroxychloroquine
(both are associated with QT prolongation),
additional data are needed prior to any recom-
mendation to utilize azithromycin as part of a
treatment regimen for COVID-19.
Ongoing Clinical Trials and Other
Considerations
As of March 20, 2020, there were 125 studies
related to COVID-19 listed on the ClinicalTria
ls.gov website. Of these, 48 were applicable to
critically ill patients and most appear to be
open-label, nonrandomized studies. In the US, a
number of studies are either close to being or
are already under way. We would like to empha-
size that at the time of publication of this paper,
there are no FDA approved treatments for severe
or critical COVID-19 that have undergone rigor-
ous scientific testing. Nevertheless, despite little
evidence for efficacy and safety, recommenda-
tions for specific pharmacotherapy are making
their way into guidance documents (e.g., Guide-
lines for the Prevention, Diagnosis, and Treat-
ment of Pneumonia Caused by COVID-19 issued
by the National Health Commission of the Peo-
ple’s Republic of China for treatment of COVID-
19),27 and hydroxychloroquine and chloroquine
have received emergency use authorization from
the FDA. Simultaneously, there are already
reports of harm from these treatments.
We strongly caution the use of unproven,
anecdotal therapies in critically ill COVID-19
patients, particularly in those with co-morbidi-
ties in which the risk of AEs and possibly inad-
vertent drug interactions can occur (seehttp://
www.covid19-druginteractions.org/ for a com-
prehensive list). It is important that we avoid
the missteps of HIV-AIDS and cyclosporine34,35
or trichosanthin.36,37 Furthermore, overuse of
such medications can lead to drug shortages for
either completion of trials or for patients that
genuinely need them. We urge providers to base
therapeutic decision making on sound scientific
evidence.
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